HKIM
NVIV

Hayek Kallen Investment Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Hayek Kallen Investment Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed -$49K – 72
2017
Q1 		$49K Hold
1
– – 0.03% 65
2016
Q4 		$50K Hold
1
– – 0.04% 63
2016
Q3 		$82K Hold
1
– – 0.06% 60
2016
Q2 		$69K Hold
1
– – 0.05% 60
2016
Q1 		$84K Hold
1
– – 0.06% 57
2015
Q4 		$79K Hold
1
– – 0.06% 56
2015
Q3 		$95K Hold
1
– – 0.07% 59
2015
Q2 		$177K Buy
+1
New +$264K 0.13% 47

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hayek Kallen Investment Management's NVIV Position: Q2 2017 in Review

Hayek Kallen Investment Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2017, closing a stake of 1 share — an estimated $49K sold.

Hayek Kallen Investment Management first reported a position in NVIV in Q2 2015 and held it in 8 quarters. The position peaked at $177K in Q2 2015. 37 funds tracked by Wall St. Rank hold NVIV as of Q2 2017.

  • Hayek Kallen Investment Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2017 after selling out during the quarter.
  • Hayek Kallen Investment Management sold 1 InVivo Therapeutics Holdings Corp share in Q2 2017, an estimated $49K.
  • Hayek Kallen Investment Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 8 quarters.
  • Hayek Kallen Investment Management's InVivo Therapeutics Holdings Corp position peaked at $177K in Q2 2015.
  • 37 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2017.

Based on Hayek Kallen Investment Management's 13F filing for Q2 2017, filed 8 Aug 2017.